Latest News

  • "Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain" published in Science Translational Medicine - August 27, 2014

  • Redwood City, CA – August 25, 2014 – Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing. The financing included new investors... read more

  • "Targeting Aldehyde Dehydrogenase 2: New Therapeutic Opportunities" published in Physiological Reviews - January 1, 2014.

  • Dr. Richard Shames joins ALDEA Pharmaceuticals as Chief Medical Officer on December 16, 2013. For Dr Shames's bio please visit our Management Team page.

  • "Variant ALDH2 is associated with accelerated progression of bone marrow failure in Fanconi anemia patients" published in BLOOD, a publication of the American Society of Hematology - October 31, 2013

  • Bill Yelle joins ALDEA Pharmaceutical as CEO on September 16, 2013.  For Bill Yelle's bio, please visit our Management Team page.